Comparing two treatments for chronic liver disease caused by Fasciola hepatica.
A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis
This study is looking at whether Oxfendazole works just as well as Triclabendazole for treating chronic fascioliasis, a liver disease caused by a parasite, and it's for people who are dealing with this condition.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Peruana Cayetano Heredia NIH-funded |
| Lab location | 1 site (Lima, Peru) |
| Project ID | NIH-10908984 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of Oxfendazole compared to Triclabendazole in treating chronic fascioliasis, a liver disease caused by a parasitic infection. Patients will be randomly assigned to receive either one or two doses of Oxfendazole or a two-dose regimen of Triclabendazole. The study aims to determine if Oxfendazole can provide a non-inferior treatment option, especially in areas where Triclabendazole is less effective due to resistance. Participants will be monitored for treatment outcomes to assess the efficacy and safety of the medications.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with chronic fascioliasis, particularly those who have not responded well to Triclabendazole.
Not a fit: Patients who are not infected with Fasciola hepatica or those who have contraindications to the study medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and accessible treatment option for patients suffering from chronic fascioliasis.
How similar studies have performed: Previous studies have shown promising results with Oxfendazole in treating other parasitic infections, suggesting potential success in this novel application.
Where this research is happening
Lima, Peru
- Universidad Peruana Cayetano Heredia — Lima, Peru (Active)
Researchers
- Principal investigator: Garcia, Hector Hugo — Universidad Peruana Cayetano Heredia
- Study coordinator: Garcia, Hector Hugo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.